UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): FEBRUARY 12, 2003

 

 

ImmunoGen, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

 

128 Sidney Street, Cambridge, MA 02139

(Address of principal executive offices)   (Zip Code)

 

 

Registrant’s telephone number, including area code: (617) 995-2500

 

 

 

 

ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS

 

(c)  Exhibits

 

Exhibit No.		Exhibit
99.1		Certification of Chief Executive Officer and Chief Financial Officer

 

ITEM 9. REGULATION FD DISCLOSURE

 

In connection with the Quarterly Report on Form 10-Q of ImmunoGen, Inc. (the “Company”) for the quarterly period ended December 31, 2002, as filed with the Securities and Exchange Commission concurrently herewith, the Company hereby files the written statement required by Section 906 of the Sarbanes-Oxley Act of 2002. On February 12, 2003, Mitchel Sayare, Chief Executive Officer and President of the Company and Gregg D. Beloff, Chief Financial Officer and Vice President, Finance of the Company, each executed this written statement. A copy of the foregoing written statement is attached hereto as an exhibit and incorporated herein by reference.

 

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

	ImmunoGen, Inc.
	(Registrant)
Date: FEBRUARY 12, 2003	/s/ Gregg D. Beloff
	Gregg D. Beloff
	Chief Financial Officer and
	Vice President, Finance

 

 

3

 

EXHIBIT INDEX

 

Exhibit No.		Exhibit
99.1		Certification of Chief Executive Officer and Chief Financial Officer

 

 

 

4